D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "buy" rating restated by research analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They currently have a $36.00 price target on the biopharmaceutical company's stock. D. Boral Capital's price objective points to a potential upside of 357.43% from the company's current price.

• Breakout Momentum Plays You Need to Know About

OMER has been the topic of a number of other reports. WBB Securities reissued a "strong-buy" rating and set a $45.00 price target on shares of Omeros in a research note on Wednesday, October 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a report on Wednesday, October 15th. HC Wainwright increased their price objective on Omeros from $9.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, October 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Omeros in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Omeros from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $33.67.

Check Out Our Latest Stock Analysis on Omeros

Omeros Price Performance

Shares of OMER stock traded up $1.59 during trading hours on Friday, hitting $7.87. 4,806,214 shares of the company's stock were exchanged, compared to its average volume of 1,622,912. Omeros has a 52 week low of $2.95 and a 52 week high of $13.60. The stock has a market cap of $535.60 million, a price-to-earnings ratio of -3.73 and a beta of 2.40. The stock's 50-day moving average is $5.71 and its 200-day moving average is $4.59.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.39. Equities research analysts forecast that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Omeros

A number of hedge funds have recently modified their holdings of OMER. Bank of New York Mellon Corp grew its holdings in Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company's stock valued at $1,242,000 after purchasing an additional 3,321 shares during the period. Harbour Investments Inc. grew its holdings in shares of Omeros by 51.9% in the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 3,149 shares during the period. Vanguard Group Inc. grew its holdings in shares of Omeros by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company's stock valued at $26,610,000 after buying an additional 95,599 shares during the period. Deutsche Bank AG raised its stake in Omeros by 4.9% during the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock worth $345,000 after buying an additional 1,973 shares during the period. Finally, Invesco Ltd. raised its stake in Omeros by 169.1% during the 1st quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company's stock worth $716,000 after buying an additional 54,696 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Featured Articles

• Five stocks we like better than Omeros
• The Risks of Owning Bonds
• Jefferies Tells NVIDIA to Step Aside, Picks Broadcom as Top Semiconductor Stock
• Where Do I Find 52-Week Highs and Lows?
• Fiserv Has NEVER Done This Before—Is It a Screaming Buy?
• What is a Special Dividend?
• Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Omeros Right Now?

Before you consider Omeros, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.

While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here